Xinguang Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 45.3362 million yuan, an increase of 19.99%

Xinguang Pharma released its third-quarter report for 2025, with operating revenue of 206 million yuan in the first three quarters, a year-on-year decrease of 4.90%. The net profit attributable to the parent company was 45.3362 million yuan, a year-on-year increase of 19.99%; the net profit excluding non-recurring gains and losses was 43.4886 million yuan, a year-on-year increase of 25.86%. The basic earnings per share were 0.28 yuan